A number of clinical studies clearly demonstrate the efficacy of hypocholesterolemic treatment in reducing incident cardiovascular events. The benefit appears to be proportional to the reduction of LDL cholesterol. Recent guidelines suggest an even more stringent target of 70 mg/dl for LDL cholesterol in high-risk subjects. Statins represent a very effective treatment of hypercholesterolemia, and the co-administration of drugs with complementary mechanisms of action, may represent an additional pharmacological tool in clinical practice to achieve the suggested targets for LDL lowering. In this short review we address the most recent discoveries in the physiological pathways of cholesterol absorption and identify the concept of dual inhibition as a therapeutic paradigm that may help in reaching the LDL cholesterol targets in clinical practice.
|Translated title of the contribution||Intestinal cholesterol absorption: A pharmacological target to control plasma cholesterol levels|
|Number of pages||6|
|Journal||Italian Heart Journal Supplement|
|Publication status||Published - 2004|
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine